Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome. Halia Therapeutics Israel Bahrain Iran Iraq Jordan Kuwait Lebanon Oman Palestine Qatar Saudi Arabia Syria United Arab Emirates Yemen India Utah

View original content:https://www.prnewswire.co.uk/news-releases/halia-therapeutics-completes-enrollment-in-phase-2a-clinical-trial-of-ht-6184-for-myelodysplastic-syndrome-mds-302472862.html